US FDA approves cancer therapy by Johnson & Johnson and Legend Biotech Reuters Mar 3, 2022 The treatment, Carvykti/Cilta-cel, belongs to a class of drugs known as CAR-T therapies, or chimeric antigen receptor T-cell…
